Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 28 | 2021 | 39 | 8.650 |
Why?
|
| Antiviral Agents | 30 | 2021 | 68 | 7.200 |
Why?
|
| Hepatitis C | 19 | 2022 | 35 | 6.450 |
Why?
|
| Liver Diseases | 13 | 2022 | 30 | 5.150 |
Why?
|
| Hepacivirus | 23 | 2022 | 26 | 4.570 |
Why?
|
| Pregnancy Complications | 8 | 2022 | 42 | 3.840 |
Why?
|
| Liver Transplantation | 9 | 2023 | 79 | 3.790 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2024 | 6 | 2.110 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2020 | 20 | 1.830 |
Why?
|
| Pregnancy | 13 | 2022 | 303 | 1.700 |
Why?
|
| Liver Cirrhosis | 12 | 2024 | 34 | 1.700 |
Why?
|
| Humans | 66 | 2024 | 22848 | 1.610 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2020 | 9 | 1.490 |
Why?
|
| Ribavirin | 8 | 2016 | 9 | 1.340 |
Why?
|
| Coinfection | 4 | 2023 | 17 | 1.280 |
Why?
|
| HIV Infections | 4 | 2021 | 369 | 1.220 |
Why?
|
| Sulfonamides | 7 | 2020 | 34 | 1.210 |
Why?
|
| Hepatitis B | 5 | 2019 | 10 | 1.180 |
Why?
|
| Female | 35 | 2024 | 12677 | 1.110 |
Why?
|
| United States | 18 | 2022 | 1726 | 1.080 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2024 | 5 | 1.020 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 98 | 0.960 |
Why?
|
| Carbamates | 9 | 2020 | 9 | 0.930 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 25 | 0.920 |
Why?
|
| Interferon-alpha | 4 | 2012 | 21 | 0.880 |
Why?
|
| Quinoxalines | 5 | 2020 | 6 | 0.880 |
Why?
|
| Polyethylene Glycols | 4 | 2012 | 36 | 0.860 |
Why?
|
| Hepatitis D | 1 | 2023 | 1 | 0.840 |
Why?
|
| Treatment Outcome | 19 | 2021 | 2960 | 0.810 |
Why?
|
| Drug Therapy, Combination | 12 | 2021 | 127 | 0.780 |
Why?
|
| Gastroenterology | 3 | 2017 | 8 | 0.770 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2021 | 32 | 0.760 |
Why?
|
| Living Donors | 1 | 2021 | 15 | 0.730 |
Why?
|
| Prejudice | 1 | 2021 | 32 | 0.720 |
Why?
|
| Patient Selection | 1 | 2021 | 157 | 0.690 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 89 | 0.690 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 93 | 0.680 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 17 | 0.680 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 20 | 0.680 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 34 | 0.680 |
Why?
|
| Benzimidazoles | 3 | 2019 | 9 | 0.670 |
Why?
|
| Genotype | 10 | 2017 | 301 | 0.650 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 1 | 0.620 |
Why?
|
| Viral Load | 5 | 2016 | 65 | 0.620 |
Why?
|
| Algorithms | 2 | 2020 | 305 | 0.610 |
Why?
|
| Obesity | 1 | 2021 | 263 | 0.610 |
Why?
|
| Adult | 19 | 2021 | 6584 | 0.610 |
Why?
|
| Sofosbuvir | 6 | 2019 | 6 | 0.600 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 6 | 2019 | 6 | 0.600 |
Why?
|
| Fear | 1 | 2018 | 17 | 0.590 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2019 | 4 | 0.570 |
Why?
|
| Liver | 3 | 2022 | 127 | 0.570 |
Why?
|
| Middle Aged | 19 | 2021 | 7555 | 0.530 |
Why?
|
| Cyclopropanes | 5 | 2020 | 9 | 0.520 |
Why?
|
| Drugs, Generic | 1 | 2016 | 1 | 0.520 |
Why?
|
| Antacids | 1 | 2016 | 1 | 0.510 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 9 | 0.510 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 3 | 0.510 |
Why?
|
| Sustained Virologic Response | 6 | 2021 | 6 | 0.500 |
Why?
|
| Virology | 1 | 2015 | 1 | 0.500 |
Why?
|
| Young Adult | 9 | 2021 | 1721 | 0.470 |
Why?
|
| Length of Stay | 2 | 2016 | 279 | 0.460 |
Why?
|
| Patient Readmission | 1 | 2016 | 116 | 0.460 |
Why?
|
| Heart Failure | 1 | 2016 | 106 | 0.450 |
Why?
|
| Liver Function Tests | 3 | 2022 | 21 | 0.450 |
Why?
|
| Risk Factors | 6 | 2023 | 1942 | 0.440 |
Why?
|
| Prognosis | 5 | 2022 | 630 | 0.430 |
Why?
|
| Prevalence | 3 | 2023 | 377 | 0.430 |
Why?
|
| Male | 21 | 2021 | 12453 | 0.430 |
Why?
|
| Advisory Committees | 1 | 2013 | 17 | 0.420 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2021 | 490 | 0.420 |
Why?
|
| Preventive Health Services | 1 | 2013 | 12 | 0.420 |
Why?
|
| Periodicals as Topic | 2 | 2023 | 33 | 0.410 |
Why?
|
| Health Policy | 1 | 2013 | 34 | 0.410 |
Why?
|
| Mass Screening | 4 | 2021 | 154 | 0.400 |
Why?
|
| Disease Management | 2 | 2016 | 82 | 0.390 |
Why?
|
| Retrospective Studies | 8 | 2024 | 3062 | 0.390 |
Why?
|
| Hepatitis C Antibodies | 2 | 2022 | 3 | 0.380 |
Why?
|
| Imidazoles | 4 | 2020 | 51 | 0.350 |
Why?
|
| Proline | 4 | 2019 | 8 | 0.350 |
Why?
|
| Lactams, Macrocyclic | 4 | 2019 | 5 | 0.350 |
Why?
|
| RNA, Viral | 4 | 2022 | 41 | 0.340 |
Why?
|
| Macrocyclic Compounds | 4 | 2019 | 4 | 0.330 |
Why?
|
| Pregnancy Outcome | 2 | 2021 | 19 | 0.330 |
Why?
|
| Drug Resistance, Viral | 4 | 2017 | 14 | 0.330 |
Why?
|
| Aged | 13 | 2020 | 7669 | 0.330 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 119 | 0.300 |
Why?
|
| Cost of Illness | 2 | 2023 | 43 | 0.300 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 2 | 0.290 |
Why?
|
| Motivation | 3 | 2023 | 71 | 0.290 |
Why?
|
| Medication Adherence | 2 | 2019 | 33 | 0.280 |
Why?
|
| Fatty Liver | 2 | 2019 | 26 | 0.280 |
Why?
|
| Recombinant Proteins | 4 | 2012 | 162 | 0.270 |
Why?
|
| Cohort Studies | 5 | 2021 | 1621 | 0.270 |
Why?
|
| Adolescent | 4 | 2020 | 1775 | 0.260 |
Why?
|
| Societies, Medical | 2 | 2017 | 101 | 0.250 |
Why?
|
| Benzofurans | 3 | 2020 | 5 | 0.250 |
Why?
|
| Graft Rejection | 2 | 2018 | 51 | 0.240 |
Why?
|
| Valine | 4 | 2019 | 5 | 0.230 |
Why?
|
| Incidence | 2 | 2020 | 649 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 104 | 0.220 |
Why?
|
| Pyrrolidines | 3 | 2018 | 6 | 0.210 |
Why?
|
| Hepatitis Delta Virus | 1 | 2023 | 1 | 0.210 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 1 | 0.210 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 3 | 0.210 |
Why?
|
| Amides | 2 | 2020 | 15 | 0.210 |
Why?
|
| Chronic Disease | 3 | 2020 | 361 | 0.210 |
Why?
|
| Benzamides | 1 | 2023 | 11 | 0.210 |
Why?
|
| Risk Assessment | 2 | 2018 | 485 | 0.200 |
Why?
|
| Vaccination | 1 | 2023 | 26 | 0.200 |
Why?
|
| Ritonavir | 3 | 2019 | 3 | 0.200 |
Why?
|
| Uracil | 3 | 2019 | 4 | 0.200 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 5 | 0.200 |
Why?
|
| RNA | 1 | 2022 | 35 | 0.200 |
Why?
|
| Fibrosis | 1 | 2022 | 29 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 4055 | 0.190 |
Why?
|
| Selection Bias | 1 | 2021 | 7 | 0.190 |
Why?
|
| Graft Survival | 2 | 2019 | 78 | 0.180 |
Why?
|
| Fertility | 1 | 2021 | 11 | 0.180 |
Why?
|
| Aminoisobutyric Acids | 2 | 2018 | 2 | 0.180 |
Why?
|
| Leucine | 2 | 2018 | 8 | 0.180 |
Why?
|
| Critical Care | 1 | 2022 | 112 | 0.180 |
Why?
|
| World Health Organization | 1 | 2020 | 9 | 0.180 |
Why?
|
| Tissue Donors | 1 | 2021 | 66 | 0.180 |
Why?
|
| Pandemics | 1 | 2022 | 201 | 0.170 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 10 | 0.170 |
Why?
|
| Recurrence | 2 | 2011 | 262 | 0.170 |
Why?
|
| Prospective Studies | 3 | 2019 | 1528 | 0.170 |
Why?
|
| Anilides | 2 | 2019 | 6 | 0.170 |
Why?
|
| 2-Naphthylamine | 2 | 2019 | 3 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 127 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2020 | 73 | 0.170 |
Why?
|
| Consensus | 2 | 2021 | 82 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 85 | 0.160 |
Why?
|
| Drug and Narcotic Control | 2 | 2016 | 3 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 17 | 0.160 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 227 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2019 | 52 | 0.160 |
Why?
|
| Internationality | 1 | 2018 | 18 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2018 | 17 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 259 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2019 | 509 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 685 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2017 | 4 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2017 | 14 | 0.140 |
Why?
|
| Psychometrics | 1 | 2018 | 172 | 0.140 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 977 | 0.130 |
Why?
|
| Patient Participation | 1 | 2017 | 39 | 0.130 |
Why?
|
| Counterfeit Drugs | 1 | 2016 | 1 | 0.130 |
Why?
|
| Hospitalization | 2 | 2016 | 272 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 5 | 0.130 |
Why?
|
| Safety | 1 | 2016 | 29 | 0.130 |
Why?
|
| Canada | 1 | 2016 | 40 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 22 | 0.130 |
Why?
|
| Commerce | 1 | 2016 | 11 | 0.130 |
Why?
|
| Ascites | 1 | 2016 | 2 | 0.130 |
Why?
|
| Paracentesis | 1 | 2016 | 3 | 0.130 |
Why?
|
| Fraud | 1 | 2016 | 17 | 0.130 |
Why?
|
| Interferons | 1 | 2016 | 8 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 102 | 0.130 |
Why?
|
| Eclampsia | 1 | 2016 | 1 | 0.130 |
Why?
|
| HELLP Syndrome | 1 | 2016 | 1 | 0.130 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 6 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2016 | 89 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 21 | 0.120 |
Why?
|
| Drug Interactions | 1 | 2015 | 28 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2015 | 10 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2015 | 82 | 0.120 |
Why?
|
| Benchmarking | 1 | 2015 | 28 | 0.120 |
Why?
|
| Time Factors | 2 | 2016 | 1220 | 0.120 |
Why?
|
| Benzazepines | 1 | 2015 | 3 | 0.120 |
Why?
|
| Isoquinolines | 1 | 2015 | 9 | 0.120 |
Why?
|
| Indoles | 1 | 2015 | 26 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2017 | 138 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 236 | 0.120 |
Why?
|
| Phenotype | 1 | 2015 | 254 | 0.110 |
Why?
|
| Hospitalists | 1 | 2014 | 3 | 0.110 |
Why?
|
| Off-Label Use | 1 | 2014 | 5 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 47 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2014 | 61 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2016 | 189 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2014 | 85 | 0.100 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2017 | 4 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2017 | 28 | 0.100 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 1 | 0.100 |
Why?
|
| Comorbidity | 3 | 2018 | 354 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 61 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2010 | 7 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2021 | 21 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 109 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2011 | 110 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2010 | 241 | 0.080 |
Why?
|
| Logistic Models | 1 | 2010 | 320 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 274 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 401 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 1494 | 0.080 |
Why?
|
| Fluorenes | 2 | 2019 | 2 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 177 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 713 | 0.070 |
Why?
|
| Hospital Costs | 2 | 2016 | 52 | 0.060 |
Why?
|
| Pyrroles | 1 | 2022 | 15 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 28 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 12 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2019 | 14 | 0.040 |
Why?
|
| Infection Control | 1 | 2021 | 169 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 29 | 0.040 |
Why?
|
| Insurance, Major Medical | 1 | 2018 | 1 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 166 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 16 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 36 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2017 | 82 | 0.030 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 1 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 13 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 41 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2018 | 116 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 39 | 0.030 |
Why?
|
| Serine Proteases | 1 | 2016 | 2 | 0.030 |
Why?
|
| Career Choice | 1 | 2016 | 25 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2016 | 23 | 0.030 |
Why?
|
| Pain Management | 1 | 2018 | 125 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 27 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 377 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 27 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 558 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 98 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 112 | 0.030 |
Why?
|
| Curriculum | 1 | 2016 | 126 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 300 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2016 | 184 | 0.030 |
Why?
|
| Drug Industry | 1 | 2014 | 6 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 37 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 44 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 110 | 0.030 |
Why?
|
| Immunoassay | 1 | 2012 | 29 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 28 | 0.020 |
Why?
|
| Probability | 1 | 2012 | 70 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 99 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 819 | 0.020 |
Why?
|